{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:27:28Z","timestamp":1780619248338,"version":"3.54.1"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,25]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Although other iatrogenic immunodeficiency-associated lymphoproliferative disorders (OIIA-LPDs) are rare, they are important adverse effects of immunosuppressive therapies. Even though anti-melanoma differentiation association gene 5 (MDA5) antibody-positive dermatomyositis requires multidrug immunosuppressive therapy for interstitial pneumonia control, OIIA-LPD has rarely been reported. Moreover, central nervous system (CNS) OIIA-LPD has never been documented. Here, we report a case of CNS OIIA-LPD that may have been caused by treatment for MDA5 antibody-positive dermatomyositis. A 53-year-old woman was diagnosed with MDA5 dermatomyositis and treated for rapidly progressive interstitial lung disease using multidrug immunosuppressive therapy with prednisolone (PSL), tacrolimus, and intravenous cyclophosphamide pulse therapy. Seven months after treatment initiation, vomiting led to the discovery of a cerebellar tumour. The cerebellar tumour was histologically Epstein\u2013Barr virus (EBV)-encoded small RNA-positive diffuse large B-cell lymphoma, with EBV-DNA being positive in the blood. The patient was diagnosed with OIIA-LPDs due to EBV reactivation. Chemotherapy, including high-dose methotrexate (MTX) and rituximab, prevented tumour recurrence without exacerbating interstitial lung disease. This is the first reported case of CNS OIIA-LPD with multidrug immunosuppression in a patient with MDA5 dermatomyositis. Chemotherapy, including high-dose MTX and rituximab, can be used for central OIIA-LPD without aggravating settled interstitial lung disease. The activity of MDA5 dermatomyositis during OIIA-LPD treatment may be managed with low-dose PSL.<\/jats:p>","DOI":"10.1093\/mrcr\/rxaf043","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T14:07:55Z","timestamp":1752847675000},"source":"Crossref","is-referenced-by-count":2,"title":["Other iatrogenic immunodeficiency-associated lymphoproliferative disorders after multidrug immunosuppressive therapy for anti-melanoma differentiation association gene 5 antibody-positive dermatomyositis: a case report"],"prefix":"10.1093","volume":"9","author":[{"given":"Shungo","family":"Mochizuki","sequence":"first","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Medical Research Institute Kitano Hospital , Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Medical Research Institute Kitano Hospital , Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Ohsumi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Medical Research Institute Kitano Hospital , Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiko","family":"Ogura","sequence":"additional","affiliation":[{"name":"Department of Hematology, Medical Research Institute Kitano Hospital , Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomi","family":"Akatsu","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Medical Research Institute Kitano Hospital , Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyoshi","family":"Takebe","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Medical Research Institute Kitano Hospital , Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Odani","sequence":"additional","affiliation":[{"name":"Department of Pathology, Medical Research Institute Kitano Hospital , Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Kitano","sequence":"additional","affiliation":[{"name":"Department of Hematology, Medical Research Institute Kitano Hospital i, Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Imura","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Medical Research Institute Kitano Hospital , Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"key":"2025081214064531500_ref1","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/art.41105","article-title":"Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive Dermatomyositis","volume":"72","author":"Tsuji","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2025081214064531500_ref2","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.3899\/jrheum.2023-0371","article-title":"Long-term prognosis of antimelanoma differentiation-associated gene 5-positive dermatomyositis with interstitial lung disease","volume":"50","author":"Sasai","year":"2023","journal-title":"J Rheumatol"},{"key":"2025081214064531500_ref3","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00296-024-05551-2","article-title":"Baricitinib for anti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis-associated interstitial lung disease: a case series and literature review on Janus kinase inhibitors for the disease","volume":"44","author":"Harada","year":"2024","journal-title":"Rheumatol Int"},{"key":"2025081214064531500_ref4","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/rheumatology\/kez357","article-title":"Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy","volume":"59","author":"Abe","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2025081214064531500_ref5","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1093\/rheumatology\/keaa123","article-title":"Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment","volume":"59","author":"Shirakashi","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2025081214064531500_ref6","volume-title":"World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2017","edition":"Revised 4th"},{"key":"2025081214064531500_ref7","volume-title":"WHO Classification of Tumors","author":"Akkari","year":"2024","edition":"5th"},{"key":"2025081214064531500_ref8","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/bjh.17824","article-title":"Retrospective analyses of other iatrogenic immunodeficiency-associated lymphoproliferative disorders in patients with rheumatic diseases","volume":"195","author":"Kaji","year":"2021","journal-title":"Br J Haematol"},{"key":"2025081214064531500_ref9","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3960\/jslrt.19007","article-title":"Clinical management for other iatrogenic immunodeficiency-associated lymphoproliferative disorders","volume":"59","author":"Tokuhira","year":"2019","journal-title":"J Clin Exp Hematop"},{"key":"2025081214064531500_ref10","doi-asserted-by":"crossref","first-page":"135","DOI":"10.5414\/NP300549","article-title":"Lymphoproliferative disease of the central nervous system in a patient with dermatomyositis on immunomodulation therapy","volume":"32","author":"Cykowski","year":"2013","journal-title":"Clin Neuropathol"},{"key":"2025081214064531500_ref11","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1111\/1756-185X.14608","article-title":"Other iatrogenic immunodeficiency-associated lymphoproliferative disorders in a patient with anti-melanoma differentiation-associated gene 5-positive dermatomyositis: a case report and systematic literature review","volume":"26","author":"Nishimura","year":"2023","journal-title":"Int J Rheum Dis"},{"key":"2025081214064531500_ref12","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1023\/A:1008201717089","article-title":"Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature","volume":"8","author":"Reni","year":"1997","journal-title":"Ann Oncol"},{"key":"2025081214064531500_ref13","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1182\/blood.2020008377","article-title":"Primary central nervous system lymphoma","volume":"140","author":"Schaff","year":"2022","journal-title":"Blood."},{"key":"2025081214064531500_ref14","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1200\/JCO.2013.50.4910","article-title":"Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome","volume":"31","author":"Morris","year":"2013","journal-title":"J Clin Oncol"},{"key":"2025081214064531500_ref15","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1182\/blood-2014-10-604561","article-title":"R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma","volume":"125","author":"Omuro","year":"2015","journal-title":"Blood."},{"key":"2025081214064531500_ref16","doi-asserted-by":"crossref","first-page":"485","DOI":"10.5692\/clinicalneurol.cn-001157","article-title":"Primary central nervous system methotrexate associated lymphoproliferative disorders in a patient with rheumatoid arthritis","volume":"58","author":"Uchida","year":"2018","journal-title":"Rinsho Shinkeigaku"},{"key":"2025081214064531500_ref17","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2176\/jns-nmc.2022-0091","article-title":"Successful treatment of intracranial methotrexate-associated lymphoproliferative disorder without Epstein-Barr virus infection using rituximab, methotrexate, procarbazine, and vincristine: a case report","volume":"9","author":"Mizushima","year":"2022","journal-title":"NMC Case Rep J"},{"key":"2025081214064531500_ref18","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1093\/rheumatology\/kel178","article-title":"Short-term and long-term outcomes of patients with anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis","volume":"45","author":"Ida","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"2025081214064531500_ref19","doi-asserted-by":"crossref","first-page":"e22978","DOI":"10.1002\/jcla.22978","article-title":"Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease","volume":"33","author":"Ye","year":"2019","journal-title":"J Clin Lab Anal"},{"key":"2025081214064531500_ref20","first-page":"168","article-title":"Rituximab in the treatment of anti-MDA5 dermatomyositis-associated interstitial lung disease: a case-based literature review. Rituximab in the treatment of anti-MDA5 dermatomyositis-associated interstitial lung disease: a case-based literature review","volume":"1","author":"Nascimento","year":"2022","journal-title":"ARP Rheumatol"},{"key":"2025081214064531500_ref21","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1093\/mrcr\/rxac060","article-title":"Clinically amyopathic dermatomyositis manifested after the allogeneic haematopoietic stem cell transplantation: case presentation and literature review","volume":"7","author":"Miyagi","year":"2023","journal-title":"Mod Rheumatol Case Rep"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxaf043\/63794527\/rxaf043.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/9\/2\/rxaf043\/63794527\/rxaf043.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/9\/2\/rxaf043\/63794527\/rxaf043.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T18:06:55Z","timestamp":1755022015000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/doi\/10.1093\/mrcr\/rxaf043\/8206121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,7,25]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxaf043","relation":{},"ISSN":["2472-5625"],"issn-type":[{"value":"2472-5625","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025]]},"published":{"date-parts":[[2025]]},"article-number":"rxaf043"}}